Spontaneous Pneumothorax

Steinhäuslin, C.A.; Cuttat, J. F.

doi:10.1378/chest.88.5.709

Cited by 95 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 11 – 26 ] In most series reported in the literature, the incidence of pneumothorax is less than 5%. [ 17 , 21 , 23 , 27 ] However, we found a higher incidence (33%) of pneumothorax in our patients: 11 of 33 patients with pulmonary nodules developed pneumothorax in various tumor types while receiving sorafenib, bevacizumab, and low-dose cyclophosphamide, while no pneumothoraces were noted in the 11 patients without pulmonary nodules. To our knowledge, this is one of the largest and most comprehensive analyses of the incidence of pneumothorax in patients receiving antiangiogenic therapy or chemotherapy.…”

Section: Discussioncontrasting

confidence: 51%

Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors

Interiano¹,

McCarville²,

Wu³

et al. 2015

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Purpose Antiangiogenic agents show significant antitumor activity against various tumor types. In a study evaluating the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors, an unexpectedly high incidence of pneumothorax was observed. We evaluated patient characteristics and risk factors for the development of pneumothorax in patients receiving this therapy. Patients and Methods Demographics, clinical course, and radiographic data of 44 patients treated with sorafenib, bevacizumab and cyclophosphamide were reviewed. Risk factors associated with the development of pneumothorax were analyzed. Results Pneumothorax likely related to study therapy developed in 11 of 44 (25%) patients of whom 33 had pulmonary abnormalities. Median age of patients was 14.7 years (range, 1.08–24.5). Histologies associated with pneumothorax included rhabdoid tumor, synovial sarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, and renal cell carcinoma. Cavitation of pulmonary nodules in response to therapy was associated with pneumothorax development (P<0.001). Median time from start of therapy to development of pneumothorax was 5.7 weeks (range, 2.4–31). Conclusion The development of cavitary pulmonary nodules in response to therapy is a risk factor for pneumothorax. As pneumothorax is a potentially life-threatening complication of antiangiogenic therapy in children with solid tumors, its risk needs to be evaluated when considering this therapy.

show abstract

Section: Discussioncontrasting

confidence: 51%

Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors

Interiano¹,

McCarville²,

Wu³

et al. 2015

Journal of Pediatric Surgery

View full text Add to dashboard Cite

show abstract

“…Pneumothorax appears to be quite rare in lung cancer patients. Steinhäuslin and Cuttat reported that among patients presenting with spontaneous pneumothorax, only 1.8% of patients had lung cancer [4]. Pneumothorax has been reported as the first sign of lung involvement for certain tumors as a complication arising from radiotherapy or cytotoxic chemotherapy in patients suffering from a variety of malignancies [5, 6].…”

Section: Discussionmentioning

confidence: 99%

“…Steinhäuslin and Cuttat reported that the occurrence of a pneumothorax neither alters the treatment of the underlying disease nor modifies the 1-year prognosis. Five-year survival is nil, suggesting that lung cancers accompanied by pneumothorax are at an advanced stage of the disease [4]. Another report indicated that pneumothorax is an ominous sign: most lung cancer patients with pneumothorax died within 3 months [7].…”

Section: Discussionmentioning

confidence: 99%

“…Several previous reports showed that the histologic types of primary lung malignant disease complicated by pneumothorax include adenocarcinoma, squamous cell carcinoma, large call carcinoma, and sarcoma [4, 7, 13–15]. However, the number of case reports of patients with pulmonary pleomorphic carcinoma increased after the disease was formally placed in the WHO histologic classification, and reports of the tendency of this disease toward necrosis and chest wall invasion are known to be more frequent [16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Pleomorphic Carcinoma Detected as a Result of Pneumothorax and the Subsequent Occurrence of Multiple Cystic Metastases

Yamakawa

Yoshida

Yabe

et al. 2014

Case Reports in Medicine

View full text Add to dashboard Cite

A 39-year-old man was admitted for spontaneous pneumothorax. He underwent pulmonary resection to correct the lesion causing the air leakage, and a pathological diagnosis of pulmonary pleomorphic carcinoma was made because we thought that the pneumothorax developed due to the direct rupture of necrotic neoplastic tissue into the pleural cavity. After the operation, the patient received chemotherapy, during which multiple cystic metastases gradually developed in the lung that caused repeated occurrences of pneumothorax. Clinicians must be careful to recognize that pneumothorax can also be a complication of primary and various metastatic pulmonary malignancies.

show abstract

“…Primary and metastatic sarcomas have been reported to be associated with spontaneous pneumothoraces and hemothoraces [ 1 - 4 ]. With the emergence and increased use of multitargeted tyrosine kinase inhibitors with anti-angiogenic effects, the risk of developing these complications is even higher [ 5 - 7 ].…”

Section: Introductionmentioning

confidence: 99%

Spontaneous Pneumothoraces and Hemothoraces in Sarcomas

Ezzeddine

Jalal

2017

Cureus

View full text Add to dashboard Cite

Spontaneous pneumothoraces and hemothoraces are rare manifestations of sarcomas occurring more commonly in specific histologic types, chemotherapy and/or anti-angiogenic therapy. Early identification of spontaneous pneumothoraces and hemothoraces improves the clinical outcomes. In this article, we present a case series of three patients with soft tissue and bone sarcomas who developed spontaneous pneumothoraces and/or hemothoraces and discuss the current literature highlighting the evidence behind these complications.

show abstract

Spontaneous Pneumothorax

Cited by 95 publications

References 30 publications

Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors

Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors

Pulmonary Pleomorphic Carcinoma Detected as a Result of Pneumothorax and the Subsequent Occurrence of Multiple Cystic Metastases

Spontaneous Pneumothoraces and Hemothoraces in Sarcomas

Contact Info

Product

Resources

About